Effects of phosphodiesterase inhibitors on interleukin-4 and interleukin-13 generation from human basophils

British Journal of Pharmacology

Volumn 142, Issue 8, 2004, Pages 1265-1272

  Eskandari, Nahid ^a   Wickramasinghe, Thulani ^a   Peachell, Peter T ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Basophils; Interleukin 13; Interleukin 4; Phosphodiesterases; Rolipram; Theophylline

Indexed keywords

3 ISOBUTYL 8 METHOXYMETHYL 1 METHYLXANTHINE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYTOKINE; DENBUFYLLINE; HISTAMINE; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 4; ISOBUTYLMETHYLXANTHINE; N HYDROXY 5,6 DIMETHOXY 2 BENZO[B]THIOPHENECARBOXIMIDAMIDE; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM; SIGUAZODAN; THEOPHYLLINE; ZAPRINAST;

ARTICLE; BASOPHIL; CONTROLLED STUDY; DRUG EFFECT; HISTAMINE RELEASE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

BASOPHILS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERLEUKIN-13; INTERLEUKIN-4; PHOSPHODIESTERASE INHIBITORS;

EID: 4444320242     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705892     Document Type: Article

References (31)

1. BEAVO, J.A., CONTI, M. & HEASLIP, R.J. (1994). Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol., 46, 399-405.
2. BEAVO, J.A. & REIFSNYDER, D.H. (1990). Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol. Sci., 11, 150-155.
3. BOURNE, H.R., LICHTENSTEIN, L.M. & MELMON, K.L. (1972). Pharmacologic control of allergic histamine release in vitro: evidence for an inhibitory role of 3'5'-adenosine monophosphate in human leukocytes. J. Immunol., 108, 695-705.
4. BOURNE, H.R., LICHTENSTEIN, L.M., MELMON, K.L., HENNEY, C.S., WEINSTEIN, Y. & SHEARER, G.M. (1974). Modulation of inflammation and immunity by cyclic AMP. Science, 184, 9-28.
5. BRUNNER, T., HEUSSER, C.H. & DAHINDEN, C.A. (1993). Human peripheral blood basophils primed by interleukin 3 (IL-3) produce IL-4 in response to immunoglobulin E receptor stimulation. J. Exp. Med., 177, 605-611.
6. CONTI, M., RICHTER, W., MEHATS, C., LIVERA, G., PARK, J.-Y. & JIN, C. (2003). Cyclic AMP-specific phosphodiesterases as critical components of cyclic AMP signaling. J. Biol. Chem., 278, 5493-5496.
7. CORRY, D.B. (1999). IL-13 in allergy: home at last. Curr. Opin. Immunol., 11, 610-614.
8. ENNIS, M. (1991). Current techniques of histamine determination. Automated fluorometric assays. Handbook Exp. Pharmacol., 97, 31-38.
9. GIBBS, B.F., HAAS, H., FALCONE, F.H., ALBRECHT, C., VOLLRATH, I.B., NOLL, T., WOLFF, H.H. & AMON, U. (1996). Purified human blood basophils release interleukin-13 and preformed interleukin-4 following immunological activation. Eur. J. Immunol., 26, 2493-2498.
10. GIBBS, B.F., VOLLRATH, I.B., ALBRECHT, C., AMON, U. & WOLFF, H.H. (1998). Inhibition of interleukin-4 and interleukin-13 release from immunologically activated human basophils due to the actions of anti-allergic drugs. Naunyn-Schmiedeberg's Arch. Pharmacol., 357, 573-578.
11. GILBERT, H.S. & ORNSTEIN, L. (1975). Basophil counting with a new staining method using Alcian Blue. Blood, 46, 279-282.
12. LICHTENSTEIN, L.M. & MARGOLIS, S. (1968). Histamine release in vitro: inhibition by catecholamines and methylxanthines. Science, 161, 902-903.
13. MACGLASHAN, D.W., WHITE, J.M., HUANG, S-K, ONO, S.J., SCHROEDER, J.T. & LICHTENSTEIN, L.M. (1994). Secretion of IL-4 from human basophils: the relationship between IL-4 mRNA and protein in resting and stimulated basophils. J. Immunol., 152, 3006-3016.
14. NICHOLSON, C.D. & SHAHID, M. (1994), Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes - their potential utility in the therapy of asthma. Pulmon. Pharmacol., 7, 1-18.
15. OCHENSBERGER, B., TASSERA, L., BIFRARE, D., RIHS, S. & DAHINDEN, C.A. (1999). Regulation of cytokine expression and leukotriene formation in human basophils by growth factors, chemokines and chemotactic agonists. Eur. J. Immunol., 29, 11-22.
16. PEACHELL, P.T., MACGLASHAN, D.W., LICHTENSTEIN, L.M. & SCHLEIMER, R.P. (1988). Regulation of human basophil and lung mast cell function by cAMP. J. Immunol., 140, 571-579.
17. PEACHELL, P.T., UNDEM, B.J., SCHLEIMER, R.P., MACGLASHAN, D.W., LICHTENSTEIN, L.M., CIESLINSKI, L.B. & TORPHY, T.J. (1992). Preliminary identification and role of phosphodiesterase isozymes in human basophils. J. Immunol., 148, 2503-2510.
18. REDRUP, A.C., HOWARD, B.P., MACGLASHAN, D.W., KAGEY-SOBOTKA, A., LICTHTENSTEIN, L.M. & SCHROEDER, J.T. (1998). Differential regulation of IL-4 and IL-13 secretion by human basophils: their relationship to histamine release in mixed leukocyte cultures. J. Immunol., 160, 1957-1964.
19. SCHROEDER, J.T., KAGEY-SOBOTKA, A. & LICHTENSTEIN, L.M. (1995). The role of the basophil in allergic inflammation. Allergy, 50, 463-472.
20. SCHROEDER, J.T., SCHLEIMER, R.P., LICHTENSTEIN, L.M. & KREUTNER, W. (2001). Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin. Exp. Allergy, 31, 1369-1377.
21. SCHWEDE, F., MARONDE, E., GENIESER, H.-G. & JASTORFF, B. (2000). Cyclic nucleotide analogs as biochemical tools and prospective drugs. Pharmacol. Ther., 87, 199-226.
22. SHICHIJO, M., SHIMIZU, Y., HIRAMATSU, K., INAGAKI, N., TAGAKI, K. & NAGAI, H. (1997). Cyclic AMP-elevating agents inhibit mite-antigen-induced IL-4 and IL-13 release from basophil-enriched leukocyte preparation. Int. Arch. Allergy Immunol., 114, 348-353.
23. SHIMIZU, Y., SHICHIJO, M., HIRAMATSU, K., TAKEUCHI, M., NAGAI, H. & TAGAKI, K. (1998). Mite-antigen-induced IL-4 and IL-13 production by basophils derived from atopic asthma patients. Clin. Exp. Allergy, 28, 497-503.
24. SIRAGANIAN, R.P. (1974). An automated continuous-flow system for the extraction and fluorometric analysis of histamine. Anal. Biochem., 57, 283-287.
25. SODERLING, S.H. & BEAVO, J.A. (2000). Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr. Opin. Cell Biol., 12, 174-179.
26. SOUNESS, J.E., ALDOUS, D. & SARGENT, C. (2000). Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology, 47, 127-162.
27. SPICUZZA, L., BELVISI, M.G., BIRRELL, M.A., BARNES, P.J., HELE, D.J. & GIEMBYCZ, M.A. (2001). Evidence that the anti-spasmogenic effect of the β-adrenoceptor agonist, isoprenaline, on guinea pig trachealis is not mediated by cyclic AMP-dependent protein kinase. Br. J. Pharmacol., 133, 1201-1212.
28. TEIXERA, M.M., GRISTWOOD, R.W., COOPER, N. & HELLEWELL, P.G. (1997). Phosphodiesterase (PDE) 4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol. Sci., 18, 164-171.
29. WARNER, J.A. & KROEGEL, C. (1994). Pulmonary immune cells in health and disease: mast cells and basophils. Eur. Respir. J., 7, 1326-1341.
30. WESTON, M.C., ANDERSON, N. & PEACHELL, P.T. (1997). Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function. Br. J. Pharmacol., 121, 287-295.
31. WILLS-KARP, M., LUYIMBAZI, J., XU, X., SCHOFIELD, B., NEBEN, T.Y., KARP, C.L. & DONALDSON, D.D. (1998). Interleukin 13: central mediator of allergic asthma. Science, 282, 2258-2261.